Summary Amplification and increased expression of many growth factor receptors, including the epidermal growth factor receptor (EGFR), has been observed in human tumours. One therapeutic strategy for overcoming EGF autocrine control of tumour growth is inhibition of EGFR protein tyrosine kinase (PTK cells after a 24 h in vitro incubation (IC50 = 11 YM and 38 gM respectively). Neither RG13022 nor its geometrical isomer displayed significant cytotoxicity. RG13022 had no influence on the growth of HN5 tumours when administered chronically, starting either on the day of tumour inoculation or after establishment of tumour xenografts. The rapid in vivo elimination of RG13022 has potential significance to the development of this and other related tyrphostin tyrosine kinase inhibitors, as plasma concentrations fell below that required for in vitro activity by 20 min post injection. The lack of in vivo tumour growth delay suggests that a more optimal administration schedule for RG13022 would include more frequent injections or continuous administration. An improved formulation for RG13022 is therefore required before further development of this or other similar protein tyrosine kinase inhibitors can be made. Alternative strategies should also be sought which display longer lasting in vivo exposures.
The recognition that many oncogene products are involved in growth factor cell signalling pathways and that their constitutive activation in tumour cells is involved in the malignant phenotype has made proteins involved in signal transduction pathways exciting targets for the development of novel anti-cancer agents (Aaronson, 1991; Brunton and Workman, 1993) . The diverse nature of these pathways leads to several possible points of pharmacological intervention, including interference with the phosphorylation of regulatory proteins via specific protein kinases. Many growth factor receptors are protein tyrosine kinases (PTKs), in which binding of ligand results in activation via phosphorylation of tyrosine residues on the receptor itself and other downstream proteins (Ullrich and Schlessinger, 1990) .
Amplification of growth factor receptors has been observed for many human cancers, including epidermal growth factor, platelet-derived growth factor, fibroblast growth factor-I and c-erbB-2 (Aaronson, 1991; Wright et al., 1989) . Epidermal growth factor receptor (EGFR) has been studied most thoroughly, with high expression found in head and neck, glioma, gynaecological and breast tumours (Harris, 1990; Mendelsohn, 1990) . In vitro data suggest that excessive activation of EGFR results in an altered cell phenotype, typical of malignancy (Stern et al., 1987) . Furthermore, increased EGFR expression correlates with a poorer clinical outcome for patients with breast and ovarian cancer (Harris, 1994; Bartlett et al., 1996) . This suggests a causal link between EGFR drive and the malignant process in man.
Several therapeutic strategies have been implemented to inactivate EGFR, including receptor antibodies, antisense oligonucleotides and PTK inhibitors. Antisense oligonucleotides for EGFR produced a reduction in cellular proliferation after prolonged incubation (Chakrabarty et al., 1995; Moroni et al., 1992) . In addition, expression of antisense EGFR RNA down-modulated the expression of EGFR and decreased matrix invasion (Chakrabarty et al., 1995) . Similar results have been observed after in vitro incubation with monoclonal antibodies directed against the EGFR, particularly in cell lines bearing large numbers of receptors (Mendelsohn, 1990 ). Significant growth delay or complete tumour regression has also been observed in human tumour xenografts after administration of EGFR monoclonal antibodies (Mendelsohn, 1990; Modjtahedi et al., 1993) . The anti-tumour activity was further enhanced by co-administration of conventional cytotoxic chemotherapy (Fan et al., 1993 (Levitzki and Gazit, 1995; Fry et al., 1994; Brunton et al., 1994; Ward et al., 1994; Traxler et al., 1995; Workman et al., 1992) . Of these compounds, the tyrphostins have been the most extensively studied (Levitzki and Gazit, 1995; Levitzki, 1990) . Potent tyrphostins with relative selectivity against various receptor and oncogene PTKs have been described, including those that inhibit EGFR in preference to the closely related c-erb-B2 (Levitzki and Gazit, 1995) . The tyrphostin RG13022 has demonstrated inhibition of breast and squamous cell carcinoma cell growth in vitro, inhibiting 50% of colony formation after a 5-10 day incubation at 1 -3 gLM concentrations (Reddy et al., 1992; Yoneda et al., 1991) . EGFR autophosphorylation was inhibited at similar concentrations (2-5 /iM) (Reddy et al., 1992; Yoneda et al., 1991 Isolation and identification of the main degradation product Preliminary investigation of RG13022 in tissue culture media and plasma observed formation of an uninidentified primary product. To determine the structure of this primary product (pp), it was isolated from plasma using a modified HPLC method and fraction collection followed by lyophilisation and identification using nuclear magnetic resonance (NMR) spectroscopy. The HPLC mobile phase was changed to water to avoid salt contamination of the substance after lyophilisation and facilitate NMR spectroscopy. The composition of the mobile phase was adjusted to 55% H20 and 45% methanol to achieve optimum separation. Signals were detected over the range of 250 nm to 400 nm. The quality of separation was checked by analysing contour plots. The mobile phase fractions containing the pp were isolated using a Waters fraction collector (Waters Chromatographic Division, Millipore, UK). An aliquot of the collected and pooled fractions was reanalysed under the same HPLC conditions to determine peak purity. The collected fractions were then lyophilised (Freeze drier Christ ALPHA, Christ, Osterode/Harz, Germany). The isolated substance (0.2 mg) was analysed in cadmium chloride by 'H-NMR spectrocopy (200 MHz) using a Briiker AM200SY instrument. (Plumb et al., 1989) . Using this protocol, the MTT assay is a measure of cytotoxicity, as cells are allowed to recover through 2-3 cell cycles post treatment in this protocol (Plumb et al., 1989) .
Results
A sensitive and precise automated HPLC assay for detection of RG13022 and related products in mouse plasma was developed. RG13022 in DMSO had a maximum absorbance (A max) at 353 nm and retention time of 21 min. The calibration curve was linear over the range 0.1 Mg ml-1 to 20 jug ml-' (r2= 0.998). The lower limit of detection was 50 ng ml-'. The assay precision, determined at 1 ,Mg ml-', had a coefficient of variation of 6.0% (n = 10).
The plasma disposition of RG13022 and its pp were characterised in MFI nu/nu mice. Four drug related peaks could be detected by HPLC. The drug-related peaks appeared at 7.4, 9.1, 13.4 and 21.3 min retention time (Figure 1 ). The peak with a retention time of 21.3 min coeluted with RG13022 and had the same spectrum. Three additional peaks were also detected in mouse plasma following intraperitoneal administration of 20 mg kg-' RG13022. The peak at 9.1 min was consistent with the pp. The peaks at 7.4 and 13.4 min were only observed in vivo and were thought to be metabolites. The maximum concentration of RG13022 in plasma, measured at the 2 min time point, was 6.3 Mg ml-' It was possible to separate and isolate the pp from tissue culture media and plasma. After lyophilisation a yellow substance was isolated and analysed by 'H-NMR spectroscopy. The geometrical (E) isomer was prepared by irradiation of RG13022 and reference spectra were obtained (Lear et al., submitted Inhibition of DNA synthesis was observed in the HN5 cells after 24h exposure to RG13022 (IC50=11.0+0.8 MM; Figure 3a) . The (E) isomer was a less potent inhibitor of 3H-thymidine incorporation (IC50 = 38.0 + 1.8 /tM Figure 3a) .
Neither RG13022 nor the geometrical isomer displayed significant cytotoxicity, with a <10% decrease in viable cells after 24 h incubation with 100 M (Figure 3b ). Chromatographic analysis of RG13022 in tissue culture media demonstrated >90% stability over 24 h at 37°C. The pp was present in tissue culture media by 3 h and reached 6% of the total tyrphostin concentration.
RG1 3022 had no influence on the growth of HN5 squamous tumours when administered once daily for 21 days starting on the day of tumour inoculation or after the tumour xenografts had grown to a volume of 50 mm3 (Figure 4) . No difference in body weight was observed for any treatment group.
Discussion
Inhibition of PTK offers a novel approach to anti-cancer drug therapy. Altering the cellular signalling response to receptor activation would provide a mechanism for slowing tumour growth and complement conventional, DNA-directed chemotherapy (Workman et al., 1992) . In particular, the tyrphostin class of PTK inhibitors have shown great promise in in vitro antiproliferative and receptor phosphorylation studies (Levitzki and Gazit, 1995; Levitzki, 1990) . The reversible nature of receptor tyrosine kinase inhibition may necessitate frequent drug administration schedules to achieve a continuous inhibition of the growth-factor stimulated proliferation. Therefore, in vivo characterisation of tyrphostin disposition is required to design schedules that would deliver sustained plasma and tissue levels. This report is the first to characterise the in vivo disposition of a tyrphostin PTK inhibitor.
RG13022 was rapidly absorbed after injection and was detectable at the earliest measured time point (2 min). The rapid absorption could be due to the hydrophobic nature and low molecular weight of the compound and may be influenced by the vehicle (DMSO). The peak plasma level was 6.34 ,ug ml-' or 28 gM. This concentration is 2.5-fold higher than the IC50 of RG13022-associated inhibition of HN5 DNA synthesis after a 24 h incubation. The concentrations needed for in vivo activity of tyrphostins are not known. It has been reported that IC5s values for the antiproliferative activity of tyrphostins in whole organ culture are 5-10 times higher than in cell culture (Dvir et al., 1991) . Nevertheless, our results, together with the report of RG13022 in vivo activity, indicate that pharmacologically relevant concentrations are achievable in vivo (Yoneda et al., 1991) . The terminal half-life of RG13022, determined from plasma samples measured over 90 min, was estimated to be 50.4 min. Although optimum assessment of terminal elimination is made after drug measurement over a 4-5 half-life time interval, RG13022 was not detectable in plasma by 2 h post injection. Therefore, it is unlikely that sufficient quantity of drug was present for continuous inhibition of receptor tyrosine kinase activity. However, caution should be applied with the extrapolation of plasma tyrphostin exposure as a surrogate marker of tumour exposure. The pharmacokinetic profile of tumour RG13022 is not known as tissue levels were not evaluated. Together with RG1 3022, three other drug-related substances were observed, with the largest peak eluting at 9 min. No standards were available, and therefore these substances could not be quantified. One of these drug-related substances showed the chromatographic and spectral characteristics of the pp. Extensive NMR spectroscopy and chromatographic analysis identified the pp as the (E) isomer of RG13022. The product was rapidly formed in vivo and had a terminal t,, of 23.9min. It is not possible to deduce from these data if the formation of this substance in vivo occurred before the absorption of the parent drug from the peritoneum or within the plasma. The pp was not detectable in the drug solution used for in vivo studies. The plasma profiles of the two other drug-related peaks reflected the production of metabolites. An initial increase in plasma concentration of these metabolites was followed by a biexponential decline. Formation of these substances before absorption, followed by a slower absorption profile than RG13022, is also possible. However, substances with similar chromatographic and spectral characteristics were not seen in vitro experiments (unpublished observations) . Yoneda et al. (1991) mentioned that RG13022 undergoes light-induced isomerisation, but assumed that the two isomeric forms were equally active. This contrasts with the al. 1991 administered RG 13022 at 200 ,ug per mouse twice daily (400 ,ug total dose), whereas in the current study we administered the same dose as a single daily injection. The rapid elimination of RG13022 resulted in plasma concentrations <1 ,IM by 20 min after injection. The rate of drug degradation of other tyrphostin compounds has also been shown to influence the degree of in vitro PTK inhibitory activity against pp6oc-src and EGFR (Ramdas et al., 1994) . The antiproliferative activity of RG13022 has an IC50 of 2-20 giM against human cancer cell lines after prolonged (> 16 h) in vitro incubations (data not shown) (Reddy et al,, 1992; Yoneda et al., 1991) . In addition, although RG1 3022 had potent inhibitory activity against HN5 fell DNA synthesis, little cytotoxic activity was observed for either RG13022 or its geometric isomer. This suggests that a better administration schedule for RG13022 would include frequent injections or continuous administration. In the current study twice daily administration of RG1 3022 was not tolerated by the MFl nu/nu mice because of the toxicity of the DMSO drug vehicle (data not shown). An improved formulation for RG1 3022 is therefore required before the in vivo activity of this PTK inhibitor can be assessed further. The results also highlight the need to develop more water-soluble tyrosine kinase inhibitors that give sustained plasma and tissue exposures, as continuous blockage of the tyrosine kinase signal is likely to be required for growth inhibition.
